These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26983672)

  • 1. Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial.
    Rief H; Omlor G; Akbar M; Bruckner T; Rieken S; Förster R; Schlampp I; Welzel T; Bostel T; Roth HJ; Debus J
    BMC Cancer; 2016 Mar; 16():231. PubMed ID: 26983672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reference intervals for serum concentrations of three bone turnover markers for men and women.
    Michelsen J; Wallaschofski H; Friedrich N; Spielhagen C; Rettig R; Ittermann T; Nauck M; Hannemann A
    Bone; 2013 Dec; 57(2):399-404. PubMed ID: 24076251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
    Alcaraz A; González-López R; Morote J; de la Piedra C; Meseguer C; Esteban E; Climent M; González-Gragera B; Alvarez-Ossorio JL; Chirivella I; Mellado B; Lara PC; Vázquez F; Contreras JA; Carles J; Murias A; Calderero V; Comet-Batlle J; González-Del Alba A; León-Mateos L; Mañas A; Segarra J; Lassa A; González-Enguita C; Méndez MJ; Samper P; Unda M; Mahillo-Fernández I; Bellmunt J;
    Br J Cancer; 2013 Jul; 109(1):121-30. PubMed ID: 23799855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
    Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors.
    Zhao H; Han KL; Wang ZY; Chen Y; Li HT; Zeng JL; Shen Z; Yao Y
    Med Sci Monit; 2011 Nov; 17(11):CR626-633. PubMed ID: 22037741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.
    Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Pons F; Martínez de Osaba MJ; Echevarría M; Ballesta AM; Muñoz-Gómez J
    Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone remodeling markers in the detection of bone metastases in prostate cancer.
    de la Piedra C; Castro-Errecaborde NA; Traba ML; Méndez-Dávila C; García-Moreno C; Rodriguez de Acuña L; Rodriguez-Molina J
    Clin Chim Acta; 2003 May; 331(1-2):45-53. PubMed ID: 12691863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reference intervals in Danish children and adolescents for bone turnover markers carboxy-terminal cross-linked telopeptide of type I collagen (β-CTX), pro-collagen type I N-terminal propeptide (PINP), osteocalcin (OC) and bone-specific alkaline phosphatase (bone ALP).
    Diemar SS; Lylloff L; Rønne MS; Møllehave LT; Heidemann M; Thuesen BH; Johannesen J; Schou AJ; Husby S; Wedderkopp N; Mølgaard C; Jørgensen NR
    Bone; 2021 May; 146():115879. PubMed ID: 33561588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between insulin-like growth factor I and bone turnover markers in the general adult population.
    Niemann I; Hannemann A; Nauck M; Spielhagen C; Völzke H; Wallaschofski H; Friedrich N
    Bone; 2013 Sep; 56(1):184-90. PubMed ID: 23792936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
    J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of palliative radiotherapy and bisphosphonate usage on bone turnover marker levels in cancer patients with osteolytic bone metastases.
    Göksel F; Akmansu M; Şentürk E; Demircioğlu F
    Jt Dis Relat Surg; 2021; 32(3):705-712. PubMed ID: 34842103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure.
    Tsuchida T; Ishimura E; Miki T; Matsumoto N; Naka H; Jono S; Inaba M; Nishizawa Y
    Osteoporos Int; 2005 Feb; 16(2):172-9. PubMed ID: 15164161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.
    Szulc P; Naylor K; Hoyle NR; Eastell R; Leary ET;
    Osteoporos Int; 2017 Sep; 28(9):2541-2556. PubMed ID: 28631236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reference intervals for bone turnover markers in Spanish premenopausal women.
    Guañabens N; Filella X; Monegal A; Gómez-Vaquero C; Bonet M; Buquet D; Casado E; Cerdá D; Erra A; Martinez S; Montalá N; Pitarch C; Kanterewicz E; Sala M; Surís X; Torres F;
    Clin Chem Lab Med; 2016 Feb; 54(2):293-303. PubMed ID: 26088062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
    Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.